Original Research
Published on 16 Nov 2023
18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China
in Hematology
![18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China](https://www.frontiersin.org/files/myhome article library/1267512/1267512_Thumb_400.jpg)
- 1,164 views